Wim Goettsch, PhD is currently Special Advisor HTA at the Dutch National Health Care Institute He was the Director of the EUnetHTA JA3 (2016-2020) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. Since 2019, he also has a position as an Associate Professor at Utrecht University (NL) where he is leading a new H2020 consortium with fifteen partners around Europe, called HTx, new methods for Health Technology Assessment (2019-2024). Between 2010 and 2015 he was the Project Leader of Work Package 5 of EUnetHTA Joint Action 1&2 in which rapid joint assessments of relative effectiveness of pharmaceuticals were piloted between more than 25 HTA organisations around Europe. Between 2010 and 2013, he was the Deputy Secretary of the Medicinal Products Reimbursement Committee at Dutch National Health Care Institute. He is currently Director of Board of HTAi (2019-2022) and has been (2013-2015) Director in the Board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and
Before joining the National Health Care Institute, he worked as a research manager for the PHARMO Institute and was responsible for coordination of numerous pharmacoepidemiological and outcomes studies for international offices of pharmaceutical companies such as AstraZeneca, Novartis, Pfizer and GSK. He also worked as a senior epidemiologist in the field of antimicrobial resistance for the National Institute for Public Health and the Environment in the Netherlands and was involved in the initiation of the European Antimicrobial Resistance Surveillance Network (EARS-Net) that is now coordinated by the ECDC. He was also seconded as a scientific secretary for Dutch National Health Council on the topic of antimicrobial growth promotors in animal feed (1997-1998). He has a PhD in immunology and an advanced education in (pharmaco)- epidemiology and pharmaco-economics. He has more than 70 publications in peer-reviewed international journals.